World

Iran's top diplomat visits Kabul to discuss refugees

Jan 27, 2025

Islamabad [Pakistan], January 27: Iranian Foreign Minister Seyed Abbas Araghchi visited Kabul on Sunday, marking the highest-level visit by an Iranian official to the Afghan capital since the Taliban's return to power in 2021.
In a statement, Afghanistan's Taliban-run foreign ministry said Araghchi met with his Afghan counterpart, Amir Khan Muttaqi, to discuss a range of issues, including economic ties, the condition of Afghan refugees and water and border issues.
Muttaqi expressed hope that Araghchi's visit would enhance relations between Afghanistan and Iran.
Muttaqi urged his Iranian counterpart to prioritize improving conditions for Afghan refugees in Iran, where millions are currently living. In recent years, Tehran has increased the forced deportation of undocumented Afghans.
Water issues between the two countries also took centre stage.
Iran has demanded more water from Afghanistan's Helmand River, while Afghanistan claims that the water level is down due to climate change and drought. But Kabul has emphasized it remains committed to the decades-old water treaty between the two countries.
According to the Afghan ministry, Araghchi praised the Taliban's government's progress, and proposed greater cooperation on combating drug trafficking and addressing water issues through technical collaboration.
Source: Qatar Tribune

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026